FDA OKs ZymoGenetics' Recothrom

01/17/2008 | Boston Globe (tiered subscription model), The

ZymoGenetics announced Thursday that the FDA has approved Recothrom Thrombin, its surgical anti-clotting product. In a late-stage trial, the drug proved as effective as bovine thrombin, a currently available product, the company said. Under terms of a global agreement, Bayer HealthCare Pharmaceuticals will back the U.S. launch of Recothrom for three years.

View Full Article in:

Boston Globe (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Actuary
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
MetLife
Bridgewater, NJ